武汉毕业科学家黄波研究出新技术让化疗药物专杀肿瘤 Graduated from wuhan scientists yellow research new technologies to ZhuanSha tumor chemotherapy drugs

　　化疗是肿瘤治疗的常用手段，但会对病人机体造成很大创伤。昨日，世界顶尖科学杂志《自然通讯(Nature　Communica-tions)》发表我国科学家黄波教授的论文，介绍一项新技术，可为解决这一困境提供新路径。

Chemotherapy is a common method of cancer treatment,But will the patient body caused great trauma.yesterday,The world's top science magazine[Natural communication(Nature Communica - tions)]Published by Chinese scientists professor yellow paper,This paper presents a new technology,In order to solve this dilemma can be provide a new path.

　　黄波2002年毕业于华中科技大学同济医学院，获生物化学与分子生物学博士学位，主要研究方向为肿瘤免疫学与肿瘤生物治疗。他及他的团队研究证实，包裹化疗药物的囊泡能够向肿瘤细胞靶向药物，在体内不引起毒副作用，且能显著抑制肿瘤的生长。该项技术已获得国家专利授权、国际专利备案和香港专利备案，并有望在武汉光谷生物城实现产业化。

Yellow in 2002, he graduated from huazhong university of tongji medical college,The biochemistry and molecular biology doctoral degree,The main research direction for tumor immunology and tumor biological treatment.He and his team study confirms,Package of chemotherapy drugs vesicles to tumor cell targeted drugs,In the body does not cause side effects,And can significantly inhibit tumor growth.The technology has been granted the national patent licensing/International patent filing and Hong Kong patent filing,Wuhan optical valley ShengWuCheng and is expected to realize industrialization.

　　黄波发表的这篇论文“肿瘤细胞来源的微颗粒靶向化疗药物”，揭示了肿瘤来源的囊泡可以作为包裹化疗药物的载体进行肿瘤治疗，与传统化疗相比，该技术能够同时解决肿瘤治疗过程中出现的化疗副作用、肿瘤耐药性、抗肿瘤免疫抑制问题，实现肿瘤化疗毒副作用、耐药性的突破。 (记者龙华、通讯员孟凡帆、实习生曾萌)

Yellow published this paper"Tumor cell sources of micro particle targeted chemotherapy drugs",Reveals the source of tumor vesicles can be used as the carrier of package chemotherapy drugs for cancer treatment,Compared with the traditional chemotherapy,This technology can also solve the cancer treatment in the process of side effects of chemotherapy/Tumor resistance/Antitumor immune rejection problem,To realize the tumor chemotherapy side effects/Resistance breakthrough. (Reporter longhua/Correspondent MengFanFan/Interns CengMeng)